首页> 美国卫生研究院文献>International Journal of Chronic Obstructive Pulmonary Disease >GOLD 2021 Strategy Report: Implications for Asthma–COPD Overlap
【2h】

GOLD 2021 Strategy Report: Implications for Asthma–COPD Overlap

机译:黄金2021战略报告:对哮喘 - COPD重叠的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease states: “we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that asthma and COPD are different disorders, although they may […] coexist in an individual patient. If a concurrent diagnosis of asthma is suspected, pharmacotherapy should primarily follow asthma guidelines, but pharmacological and non-pharmacological approaches may also be needed for their COPD.” What does this mean for the treating physician? In this review, we explore the implications of this new guidance on treating patients with chronic obstructive pulmonary disease, arguing for a personalized approach to treatment.
机译:在其2021年战略报告中,慢性阻塞性肺病的全球倡议国家:“我们不再指哮喘 - COPD重叠(ACO),相反,我们强调哮喘和COPD是不同的障碍,尽管他们可能会在一个中共存个体患者。如果怀疑哮喘的并发诊断,药物疗法应主要遵循哮喘准则,但也可能需要药理学和非药理学方法。“这对治疗医师意味着什么?在这篇综述中,我们探讨了这种新指导对治疗慢性阻塞性肺病患者的影响,争论了个性化的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号